Eszopiklon etkileşimleri
sedatif-hipnotik sınıfından Eszopiklon (Lunesta) için dizinlediğimiz FDA etiketlerinde ve bilgi sayfalarında 261 belgelenmiş etkileşim var: 180 majör, 76 orta, 4 minör ve bir etiketin anlamlı etkileşim olmadığını bildirdiği 1 çift. Aşağıdaki her kayıt, dayandığı cümleyi alıntılar. Bu ilaç sayfası bir başlangıç noktasıdır; sizin durumunuz için verilmiş bir hüküm değildir.
Etikete göre etkileşimler
Majör etkileşimler (180)
Alkolün sedasyon yapan ilaçlarla (opioidler, benzodiazepinler, uyku ilaçları, kas gevşeticiler) birlikte alınması tehlikeli uyuşukluğa, solunumun yavaşlamasına ve aşırı doza yol açabilir. (NIAAA, Harmful Interactions: Mixing Alcohol with Medicines)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
CONTRAINDICATIONS Diphenoxylate hydrochloride and atropine sulfate is contraindicated in: • Pediatric patients less than 6 years of age due to the risks of respiratory and central nervous system (CNS) depression (see WARNINGS ). (Difenoksilat ve atropin etiketi, Kontrendikasyonlar)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
…Lipid-modifying Agents: lomitapide, lovastatin, simvastatin Phosphodiesterase-5 (PDE-5) Inhibitor: sildenafil when administered as REVATIO ® for the treatment of pulmonary arterial hypertension Sedative/hypnotics: triazolam, orally administered midazolam Coadministration of GENVOYA is contraindicated with drugs that: Are highly dependent on CYP3A for clearance and for which… (Elvitegravir, kobisistat, emtrisitabin ve tenofovir etiketi, Kontrendikasyonlar)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
Phenelzine sulfate should not be used in combination with dextromethorphan or with CNS depressants such as alcohol and certain narcotics. (Fenelzin etiketi, Kontrendikasyonlar)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
This may potentiate and prolong hypnotic and sedative effects, especially with repeated dosing or chronic administration of these agents. (Ketokonazol etiketi, Kontrendikasyonlar)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
Avoid concurrent use of alcohol or other central nervous system depressants with XYZAL. (Levosetirizin etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
Risk of Recurrent Respiratory and CNS Depression : A recurrence of respiratory depression is possible, therefore, keep the patient under continued surveillance and administer repeat doses of ZURNAI using a new auto-injector with each dose while awaiting emergency medical assistance. (Nalmefen etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
• Avoid concurrent use of alcohol or other central nervous system depressants with olopatadine hydrochloride nasal solution (nasal spray) ( 5.2 ). (Olopatadin etiketi, Uyarılar ve önlemler)
• Avoid concurrent use of alcohol or other central nervous system (CNS) depressants with RYALTRIS because additional reductions in alertness and additional impairment of CNS performance may occur. (Olopatadin ve mometazon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
Avoid concurrent use of QUZYTTIR with alcohol or other CNS depressants because additional reduction in alertness and additional impairment of CNS performance may occur. (Setirizin etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
Table 8: Drugs That are Affected by and Affecting Ciprofloxacin Drugs That are Affected by Ciprofloxacin Drug(s) Recommendation Comments Tizanidine Contraindicated Concomitant administration of tizanidine and ciprofloxacin is contraindicated due to the potentiation of hypotensive and sedative effects of tizanidine [see Contraindications ( 4.2 )]. (Siprofloksasin etiketi, İlaç etkileşimleri)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (Eszopiklon etiketi, Uyarılar ve önlemler)
Orta düzey etkileşimler (76)
Inform patients also that the central nervous system depressant effects of allopurinol tablets may be additive to those of alcohol and other CNS depressants. (Allopurinol etiketi, Uyarılar ve önlemler)
25% increase Diazepam Benzodiazepines increase CNS concentrations of adenosine, a potent CNS depressant, while theophylline blocks adenosine receptors. (Aminofilin etiketi, İlaç etkileşimleri)
The dose of LUNESTA should be reduced in patients who are administered potent inhibitors of CYP3A4, such as ketoconazole, while taking LUNESTA. (Eszopiklon etiketi, Uyarılar ve önlemler)
The dose of LUNESTA should be reduced in patients who are administered potent inhibitors of CYP3A4, such as ketoconazole, while taking LUNESTA. (Eszopiklon etiketi, Uyarılar ve önlemler)
Drugs that Induce CYP3A4 (Rifampicin) Racemic zopiclone exposure was decreased 80% by concomitant use of rifampicin, a potent inducer of CYP3A4. (Eszopiklon etiketi, İlaç etkileşimleri)
Sedatives/Hypnotics: midazolam (oral) triazolam ↑ midazolam (oral) ↑ triazolam Use caution when midazolam or triazolam is concomitantly administered with BIXLENVO. (Biktegravir, emtrisitabin ve tenofovir alafenamid etiketi, İlaç etkileşimleri)
Drugs that Induce CYP3A4 (Rifampicin) Racemic zopiclone exposure was decreased 80% by concomitant use of rifampicin, a potent inducer of CYP3A4. (Eszopiklon etiketi, İlaç etkileşimleri)
Use with CNS depressants may result in an additive or potentiating effect. (Brimonidin etiketi, İlaç etkileşimleri)
Use with CNS depressants may result in an additive or potentiating effect. (Brimonidin ve timolol etiketi, İlaç etkileşimleri)
Possible early warning signs of central nervous system (CNS) toxicity are restlessness, anxiety, incoherent speech, lightheadedness, numbness and tingling of the mouth and lips, metallic taste, tinnitus, dizziness, blurred vision, tremors, twitching, CNS depression, or drowsiness. (Bupivakain etiketi, Uyarılar ve önlemler)
Possible early warning signs of central nervous system (CNS) toxicity are restlessness, anxiety, incoherent speech, lightheadedness, numbness and tingling of the mouth and lips, metallic taste, tinnitus, dizziness, blurred vision, tremors, twitching, CNS depression, or drowsiness. (Bupivakain ve adrenalin etiketi, Uyarılar ve önlemler)
Additive effects occur with concomitant use of other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol), including daytime use. (Eszopiklon etiketi, Uyarılar ve önlemler)
Triazolam/flurazepam: Coadministration of buspirone with either triazolam or flurazepam did not appear to prolong or intensify the sedative effects of either benzodiazepine. (Buspiron etiketi, İlaç etkileşimleri)
Drugs that Induce CYP3A4 (Rifampicin) Racemic zopiclone exposure was decreased 80% by concomitant use of rifampicin, a potent inducer of CYP3A4. (Eszopiklon etiketi, İlaç etkileşimleri)
Drugs that Induce CYP3A4 (Rifampicin) Racemic zopiclone exposure was decreased 80% by concomitant use of rifampicin, a potent inducer of CYP3A4. (Eszopiklon etiketi, İlaç etkileşimleri)
Additive effects occur with concomitant use of other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol), including daytime use. (Eszopiklon etiketi, Uyarılar ve önlemler)
The dose of LUNESTA should be reduced in patients who are administered potent inhibitors of CYP3A4, such as ketoconazole, while taking LUNESTA. (Eszopiklon etiketi, Uyarılar ve önlemler)
Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)
The dose of LUNESTA should be reduced in patients who are administered potent inhibitors of CYP3A4, such as ketoconazole, while taking LUNESTA. (Eszopiklon etiketi, Uyarılar ve önlemler)
Additive effects occur with concomitant use of other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol), including daytime use. (Eszopiklon etiketi, Uyarılar ve önlemler)
The dose of LUNESTA should be reduced in patients who are administered potent inhibitors of CYP3A4, such as ketoconazole, while taking LUNESTA. (Eszopiklon etiketi, Uyarılar ve önlemler)
The dose of LUNESTA should be reduced in patients who are administered potent inhibitors of CYP3A4, such as ketoconazole, while taking LUNESTA. (Eszopiklon etiketi, Uyarılar ve önlemler)
CNS Depressant Effects: Impaired alertness and motor coordination, including risk of morning impairment. (Eszopiklon etiketi, Uyarılar ve önlemler)
The dose of LUNESTA should be reduced in patients who are administered potent inhibitors of CYP3A4, such as ketoconazole, while taking LUNESTA. (Eszopiklon etiketi, Uyarılar ve önlemler)
Additive effects occur with concomitant use of other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol), including daytime use. (Eszopiklon etiketi, Uyarılar ve önlemler)
Drugs that Induce CYP3A4 (Rifampicin) Racemic zopiclone exposure was decreased 80% by concomitant use of rifampicin, a potent inducer of CYP3A4. (Eszopiklon etiketi, İlaç etkileşimleri)
The dose of LUNESTA should be reduced in patients who are administered potent inhibitors of CYP3A4, such as ketoconazole, while taking LUNESTA. (Eszopiklon etiketi, Uyarılar ve önlemler)
The dose of LUNESTA should be reduced in patients who are administered potent inhibitors of CYP3A4, such as ketoconazole, while taking LUNESTA. (Eszopiklon etiketi, Uyarılar ve önlemler)
Additive effects occur with concomitant use of other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol), including daytime use. (Eszopiklon etiketi, Uyarılar ve önlemler)
Additive effects occur with concomitant use of other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol), including daytime use. (Eszopiklon etiketi, Uyarılar ve önlemler)
The dose of LUNESTA should be reduced in patients who are administered potent inhibitors of CYP3A4, such as ketoconazole, while taking LUNESTA. (Eszopiklon etiketi, Uyarılar ve önlemler)
Drugs that Induce CYP3A4 (Rifampicin) Racemic zopiclone exposure was decreased 80% by concomitant use of rifampicin, a potent inducer of CYP3A4. (Eszopiklon etiketi, İlaç etkileşimleri)
The dose of LUNESTA should be reduced in patients who are administered potent inhibitors of CYP3A4, such as ketoconazole, while taking LUNESTA. (Eszopiklon etiketi, Uyarılar ve önlemler)
The dose of LUNESTA should be reduced in patients who are administered potent inhibitors of CYP3A4, such as ketoconazole, while taking LUNESTA. (Eszopiklon etiketi, Uyarılar ve önlemler)
The dose of LUNESTA should be reduced in patients who are administered potent inhibitors of CYP3A4, such as ketoconazole, while taking LUNESTA. (Eszopiklon etiketi, Uyarılar ve önlemler)
The dose of LUNESTA should be reduced in patients who are administered potent inhibitors of CYP3A4, such as ketoconazole, while taking LUNESTA. (Eszopiklon etiketi, Uyarılar ve önlemler)
The dose of LUNESTA should be reduced in patients who are administered potent inhibitors of CYP3A4, such as ketoconazole, while taking LUNESTA. (Eszopiklon etiketi, Uyarılar ve önlemler)
The dose of LUNESTA should be reduced in patients who are administered potent inhibitors of CYP3A4, such as ketoconazole, while taking LUNESTA. (Eszopiklon etiketi, Uyarılar ve önlemler)
Additive effects occur with concomitant use of other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol), including daytime use. (Eszopiklon etiketi, Uyarılar ve önlemler)
Possible early warning signs of central nervous system (CNS) toxicity are restlessness, anxiety, incoherent speech, lightheadedness, metallic taste, tinnitus, dizziness, blurred vision, tremors, twitching, CNS depression, or drowsiness. (Lidokain ve adrenalin etiketi, Uyarılar ve önlemler)
Drugs that Induce CYP3A4 (Rifampicin) Racemic zopiclone exposure was decreased 80% by concomitant use of rifampicin, a potent inducer of CYP3A4. (Eszopiklon etiketi, İlaç etkileşimleri)
- MetirozinOrta
Concurrent use of metyrosine with alcohol or other CNS depressants can increase their sedative effects. (Metirozin etiketi, İlaç etkileşimleri)
The dose of LUNESTA should be reduced in patients who are administered potent inhibitors of CYP3A4, such as ketoconazole, while taking LUNESTA. (Eszopiklon etiketi, Uyarılar ve önlemler)
The dose of LUNESTA should be reduced in patients who are administered potent inhibitors of CYP3A4, such as ketoconazole, while taking LUNESTA. (Eszopiklon etiketi, Uyarılar ve önlemler)
Drugs that Induce CYP3A4 (Rifampicin) Racemic zopiclone exposure was decreased 80% by concomitant use of rifampicin, a potent inducer of CYP3A4. (Eszopiklon etiketi, İlaç etkileşimleri)
Drugs that Induce CYP3A4 (Rifampicin) Racemic zopiclone exposure was decreased 80% by concomitant use of rifampicin, a potent inducer of CYP3A4. (Eszopiklon etiketi, İlaç etkileşimleri)
Drugs that Induce CYP3A4 (Rifampicin) Racemic zopiclone exposure was decreased 80% by concomitant use of rifampicin, a potent inducer of CYP3A4. (Eszopiklon etiketi, İlaç etkileşimleri)
Drugs that Induce CYP3A4 (Rifampicin) Racemic zopiclone exposure was decreased 80% by concomitant use of rifampicin, a potent inducer of CYP3A4. (Eszopiklon etiketi, İlaç etkileşimleri)
WARNINGS AND PRECAUTIONS Risk of Recurrent Respiratory and CNS Depression : Due to the duration of action of naloxone relative to the opioid, respiratory and CNS depression may recur after the first dose of naloxone. (Nalokson etiketi, Uyarılar ve önlemler)
Additive effects occur with concomitant use of other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol), including daytime use. (Eszopiklon etiketi, Uyarılar ve önlemler)
Additive effects occur with concomitant use of other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol), including daytime use. (Eszopiklon etiketi, Uyarılar ve önlemler)
Drugs that Induce CYP3A4 (Rifampicin) Racemic zopiclone exposure was decreased 80% by concomitant use of rifampicin, a potent inducer of CYP3A4. (Eszopiklon etiketi, İlaç etkileşimleri)
The dose of LUNESTA should be reduced in patients who are administered potent inhibitors of CYP3A4, such as ketoconazole, while taking LUNESTA. (Eszopiklon etiketi, Uyarılar ve önlemler)
Additive effects occur with concomitant use of other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol), including daytime use. (Eszopiklon etiketi, Uyarılar ve önlemler)
CNS Depressant Effects: Impaired alertness and motor coordination, including risk of morning impairment. (Eszopiklon etiketi, Uyarılar ve önlemler)
The dose of LUNESTA should be reduced in patients who are administered potent inhibitors of CYP3A4, such as ketoconazole, while taking LUNESTA. (Eszopiklon etiketi, Uyarılar ve önlemler)
The dose of LUNESTA should be reduced in patients who are administered potent inhibitors of CYP3A4, such as ketoconazole, while taking LUNESTA. (Eszopiklon etiketi, Uyarılar ve önlemler)
Drugs that Induce CYP3A4 (Rifampicin) Racemic zopiclone exposure was decreased 80% by concomitant use of rifampicin, a potent inducer of CYP3A4. (Eszopiklon etiketi, İlaç etkileşimleri)
Drugs that Induce CYP3A4 (Rifampicin) Racemic zopiclone exposure was decreased 80% by concomitant use of rifampicin, a potent inducer of CYP3A4. (Eszopiklon etiketi, İlaç etkileşimleri)
Drugs that Induce CYP3A4 (Rifampicin) Racemic zopiclone exposure was decreased 80% by concomitant use of rifampicin, a potent inducer of CYP3A4. (Eszopiklon etiketi, İlaç etkileşimleri)
Additive effects occur with concomitant use of other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol), including daytime use. (Eszopiklon etiketi, Uyarılar ve önlemler)
The dose of LUNESTA should be reduced in patients who are administered potent inhibitors of CYP3A4, such as ketoconazole, while taking LUNESTA. (Eszopiklon etiketi, Uyarılar ve önlemler)
The dose of LUNESTA should be reduced in patients who are administered potent inhibitors of CYP3A4, such as ketoconazole, while taking LUNESTA. (Eszopiklon etiketi, Uyarılar ve önlemler)
Additive effects occur with concomitant use of other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol), including daytime use. (Eszopiklon etiketi, Uyarılar ve önlemler)
Drugs that Induce CYP3A4 (Rifampicin) Racemic zopiclone exposure was decreased 80% by concomitant use of rifampicin, a potent inducer of CYP3A4. (Eszopiklon etiketi, İlaç etkileşimleri)
25% increase Diazepam Benzodiazepines increase CNS concentrations of adenosine, a potent CNS depressant, while theophylline blocks adenosine receptors. (Teofilin etiketi, İlaç etkileşimleri)
The dose of LUNESTA should be reduced in patients who are administered potent inhibitors of CYP3A4, such as ketoconazole, while taking LUNESTA. (Eszopiklon etiketi, Uyarılar ve önlemler)
Additive effects occur with concomitant use of other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol), including daytime use. (Eszopiklon etiketi, Uyarılar ve önlemler)
Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (Triheksifenidil etiketi, İlaç etkileşimleri)
- TrimetobenzamidOrta
The recent use of other drugs that cause CNS depression or EPS symptoms may also increase the risk; consider reducing the dosage or discontinuing the drug. (Trimetobenzamid etiketi, Uyarılar ve önlemler)
Additive effects occur with concomitant use of other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol), including daytime use. (Eszopiklon etiketi, Uyarılar ve önlemler)
The dose of LUNESTA should be reduced in patients who are administered potent inhibitors of CYP3A4, such as ketoconazole, while taking LUNESTA. (Eszopiklon etiketi, Uyarılar ve önlemler)
Additive effects occur with concomitant use of other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol), including daytime use. (Eszopiklon etiketi, Uyarılar ve önlemler)
The dose of LUNESTA should be reduced in patients who are administered potent inhibitors of CYP3A4, such as ketoconazole, while taking LUNESTA. (Eszopiklon etiketi, Uyarılar ve önlemler)
Additive effects occur with concomitant use of other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol), including daytime use. (Eszopiklon etiketi, Uyarılar ve önlemler)
Minör değinmeler (4)
Antihistamines Amphetamines may counteract the sedative effect of antihistamines. (Dekstroamfetamin etiketi, İlaç etkileşimleri)
- DoksapramMinör
In Drug-Induced CNS and Respiratory Depression Doxapram alone may not stimulate adequate spontaneous breathing or provide sufficient arousal in patients who are severely depressed either due to respiratory failure or to CNS depressant drugs, but may be used as an adjunct to established supportive measures and resuscitative techniques. (Doksapram etiketi, Uyarılar)
- Epoetin alfaMinör
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (Epoetin alfa etiketi, Uyarılar ve önlemler)
…to date with the following: (1) cardiac glycosides– digitalis and digoxin; (2) hypoglycemics–insulin, chlorpropamide, phenformin, tolazamide, and tolbutamide; (3) tranquilizers and sedatives–chlordiazepoxide, diazepam, and phenobarbital; (4) antigout–allopurinol, colchicine, and probenecid; (5) antiarrhythmics–procainamide, propranolol (see WARNINGS however),… (Prazosin etiketi, İlaç etkileşimleri)
Anlamlı etkileşim olmadığı bildirilenler (1)
…adjustment is needed when SINGULAIR is co-administered with theophylline, prednisone, prednisolone, oral contraceptives, fexofenadine, digoxin, warfarin, gemfibrozil, itraconazole, thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, decongestants, and Cytochrome P450 (CYP) enzyme inducers [see Clinical Pharmacology (12.3) ]. (Montelukast etiketi, İlaç etkileşimleri)
Kullandığınız her şeyi Eszopiklon ile karşılaştırın. Tüm listenizi ekleyin; her çift tek seferde kontrol edilir.
Sorgulama aracında açTıbbi tavsiye değildir. Şiddet derecesi sizin koşullarınızı değil, etiketin ifadesini yansıtır. “Majör” işareti gözetim altında olağan bir uygulama olabilir, “minör” işareti ise yüksek dozlarda önem kazanabilir. Bir eczacıya danışın.